3 shares
A vial of Russia s experimental Sputnik V coronavirus vaccine, in Moscow, Russia, September 15, 2020. (Alexander Zemlianichenko Jr/AP)
TEHRAN, Iran A first batch of Russia’s Sputnik V vaccine arrived Thursday in Iran, the regional country hardest hit by the pandemic, which has charged US sanctions have hindered its fight against COVID-19.
“The first shipment of vaccines from Moscow… has landed at Imam Khomeini airport in Tehran,” state news agency IRNA reported, without specifying the number of doses.
The second and third deliveries of the vaccine are due to be sent to Tehran on February 18 and 28, IRNA quoted Kazem Jalali, Iran’s ambassador to Moscow, as saying.
Red Cross boosts COVID-19 vaccine hopes for poor as jabs arrive in Iran channelnewsasia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from channelnewsasia.com Daily Mail and Mail on Sunday newspapers.
AstraZeneca, Oxford say COVID-19 vaccine 76% effective after 90 days
By (0)
The pharmaceutical company said the research also shows the vaccine is 100% effective in preventing severe cases of the coronavirus disease. Photo courtesy AstraZeneca/Oxford
Feb. 3 (UPI) The COVID-19 vaccine in development by AstraZeneca and Britain s Oxford University has shown in clinical trials to be 76% effective against the coronavirus after 90 days, researchers said Wednesday.
Data from a primary analysis of third-stage trials, published in a manuscript in The Lancet medical journal, showed the vaccine s effectiveness.
Advertisement
The pharmaceutical company said the research also shows the vaccine is 100% effective in preventing severe cases of the coronavirus disease. No trial volunteers died or were hospitalized, either, it said.
EU regulators approve AstraZeneca COVID-19 vaccine
By (0)
A nurse prepares to administer a dose of the COVID-19 vaccine. The EU s top pharmaceutical regulator on Friday approved a vaccine developed by AstraZeneca and Britain s Oxford University. Photo by Debbie Hill/UPI | License Photo
Jan. 29 (UPI) European Union regulators on Friday gave approval to AstraZeneca s coronavirus vaccine for emergency use in all adults, despite a lack of data for those 65 and older.
The European Medicines Agency, the EU s chief drug regulator, gave the authorization.
Advertisement
AstraZeneca now must receive conditional marketing authorization from the European Union to begin distribution. If authorized, it would become the third vaccine available in the bloc, after vaccines developed by Pfizer and Moderna.